ADVFN US – Market Content Editor
-
SU Group Shares Double After Securing Landmark $11.3M Smart Hospital Contract
Shares of SU Group Holdings Limited (NASDAQ:SUGP) surged 125% in pre-market trading following news that the Hong Kong-based security engineering firm has landed the largest deal in its corporate history. Valued at $11.3 million (HK$88.5 million), the newly awarded contract involves deploying an advanced suite of security and monitoring technologies as part of a large-scale…
-
Artelo Biosciences Shares Climb on Promising Preclinical Osteoarthritis Pain Data
Artelo Biosciences Inc (NASDAQ:ARTL) saw its stock jump 10% after unveiling encouraging preclinical results for its lead drug candidate, ART26.12, at the 35th Annual International Cannabinoid Research Society Symposium. The investigational therapy—designed as a non-opioid, non-steroidal fatty acid binding protein 5 (FABP5) inhibitor—demonstrated strong analgesic effects in a model of osteoarthritis pain. According to the…
-
BriaCell Shares Slide 22% After Announcing Dilutive Public Offering
Shares of BriaCell Therapeutics Corp (NASDAQ:BCTX) dropped 22% after the clinical-stage biotech firm unveiled a public offering likely to dilute existing shareholders. The company announced it will offer up to 6,825,938 common units on a best efforts basis, with each unit priced at $2.93. Each unit consists of one common share and one warrant allowing…
-
InspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid Stent
InspireMD Inc. (NASDAQ:NSPR) saw its shares rise 4% in premarket trading after the company officially launched its CGuard Prime carotid stent system in the U.S. market. The commercial debut follows the product’s premarket approval by the U.S. Food and Drug Administration. CGuard Prime is engineered to reduce the risk of embolism both shortly after and…
-
Kazia Therapeutics Shares Surge on Promising Initial Data from Cancer Trial
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its stock jump 45% after unveiling preliminary data from the first patient enrolled in its Phase 1b study evaluating a new combination therapy for metastatic triple-negative breast cancer. The company highlighted that the patient, a 61-year-old woman, experienced a greater than 50% reduction in circulating tumor cells (CTCs) along…
-
Classover Shares Jump After Boosting Solana Holdings Nearly 300%
Shares of Classover Holdings Inc (NASDAQ:KIDZ) soared 25% following the company’s announcement that it has dramatically increased its reserves of Solana (SOL), a leading blockchain token. The online education firm disclosed that it has grown its SOL holdings by approximately 295% since its last update on June 12, raising the total to 52,067 tokens. According…
-
Evoke Pharma Shares Jump 50% Following Patent Approval for GIMOTI
Evoke Pharma Inc (NASDAQ:EVOK) saw its stock soar 50% after the specialty pharma company received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application covering GIMOTI, its treatment for gastroparesis. The newly allowed patent application is a continuation of U.S. Patent No. 11,517,545 and strengthens Evoke’s intellectual property protection…
-
Rhythm Pharmaceuticals Shares Jump Following Promising Phase 2 Data for Obesity Drug
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) saw its stock rise by 10% after unveiling encouraging topline results from its Phase 2 clinical trial assessing bivamelagon, a novel oral melanocortin-4 receptor agonist, in patients suffering from acquired hypothalamic obesity. The biopharma company revealed that bivamelagon produced statistically significant and clinically meaningful decreases in body mass index (BMI) after…
-
Dow Jones, S&P, Nasdaq, U.S. Stocks Set for a Positive Start Amid Trade Deal Optimism and Fed Watch
U.S. stock futures indicate a modest gain for Wednesday’s open as investors look to bounce back following a mostly flat and volatile session on Tuesday. Market sentiment is buoyed by reports that the U.S. and European Union are closing in on a trade agreement, potentially involving tariffs higher than those applied to the U.K. The…
-
Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition
Tandem Diabetes Care (NASDAQ:TNDM) saw its stock decline by 5% Wednesday morning after Citi downgraded the company from Neutral to Sell, citing increasing challenges from competitors. Analyst Joanne Wuensch cut her price target sharply, lowering it from $24 to $14, suggesting a downside of about 16% compared to Tuesday’s closing price of $16.62. The downgrade…